See the DrugPatentWatch profile for tetrabenazine
What is Deuterated Tetrabenazine?
Deuterated tetrabenazine, known by its brand name deutetrabenazine, is a medication used to treat chorea associated with Huntington's disease and tardive dyskinesia [1]. It is a deuterated form of tetrabenazine, meaning that some hydrogen atoms in the molecule have been replaced with deuterium, a heavier isotope of hydrogen [2]. This modification alters the drug's metabolism, potentially leading to a more stable and predictable plasma concentration compared to the original tetrabenazine [3].
How Does Deuterated Tetrabenazine Work?
Deuterated tetrabenazine functions by inhibiting the vesicular monoamine transporter 2 (VMAT2) [2]. VMAT2 is responsible for transporting monoamines, such as dopamine, into synaptic vesicles for storage and release. By blocking VMAT2, deutetrabenazine reduces the amount of dopamine available for release in the brain, which is believed to be responsible for alleviating the involuntary movements associated with Huntington's disease and tardive dyskinesia [4].
Why Was Deuterated Tetrabenazine Developed?
The development of deuterated tetrabenazine aimed to improve upon the pharmacokinetic profile of tetrabenazine [3]. Tetrabenazine has a short half-life and undergoes rapid metabolism, leading to significant fluctuations in drug levels. The deuteration of tetrabenazine results in a slower metabolic breakdown, allowing for less frequent dosing and potentially a more consistent therapeutic effect with a reduced risk of peak-concentration-related side effects [3][5].
When Does Deuterated Tetrabenazine's Patent Expire?
Patent information for deuterated tetrabenazine can be complex, involving multiple patents covering the compound, its manufacturing processes, and its uses. According to DrugPatentWatch.com, there are numerous patents associated with deutetrabenazine. For detailed information on specific patent expiry dates, it is recommended to consult specialized resources like DrugPatentWatch.com [6].
What Are the Side Effects of Deuterated Tetrabenazine?
Common side effects associated with deuterated tetrabenazine include sleepiness, fatigue, and Parkinsonism (symptoms such as slow movement, stiffness, and tremors) [1]. Depression and suicidal thoughts are also potential serious side effects that require immediate medical attention [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
How Does Deuterated Tetrabenazine Compare to Tetrabenazine?
The primary difference between deuterated tetrabenazine and tetrabenazine lies in their pharmacokinetic properties. Deuterated tetrabenazine has a longer half-life and exhibits less variability in plasma concentrations due to its slower metabolism, allowing for twice-daily dosing [5]. Tetrabenazine, in contrast, is metabolized more rapidly and typically requires more frequent dosing [3]. This improved pharmacokinetic profile is the key advantage of the deuterated version.
What Other Treatments Are Available for Chorea and Tardive Dyskinesia?
In addition to deuterated tetrabenazine, other treatment options for chorea associated with Huntington's disease and tardive dyskinesia exist. These may include other VMAT2 inhibitors like valbenazine, as well as off-label use of other medications and supportive care [7][8]. The choice of treatment depends on the individual patient's condition, medical history, and response to therapy.
---
Sources:
[1] https://www.drugs.com/deutetrabenazine.html
[2] https://pubchem.ncbi.nlm.nih.gov/compound/Deutetrabenazine
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936994/
[4] https://www.neurology.org/doi/10.1212/01.wnl.0000530000.80733.78
[5] https://jamanetwork.com/journals/jama/fullarticle/2610480
[6] https://drugpatentwatch.com/
[7] https://www.hopkinsmedicine.org/health/conditions-and-diseases/huntingtons-disease/chorea
[8] https://www.mayoclinic.org/diseases-conditions/tardive-dyskinesia/diagnosis-treatment/drc-20377970